Patents by Inventor Göran Alderborn

Göran Alderborn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS
    Publication number: 20240342096
    Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
    Type: Application
    Filed: April 10, 2024
    Publication date: October 17, 2024
    Applicant: EMPROS PHARMA AB
    Inventors: Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
  • SYNERGISTIC EFFECTS ON WEIGHT LOSS, IMPROVED QUALITY OF LIFE AND REDUCED GASTRO-INTESTINAL SIDE EFFECTS WITH A COMPOSITION OF ORLISTAT AND ACARBOSE
    Publication number: 20240226024
    Abstract: The invention relates to a composition of orlistat and acarbose for use in improving quality of life. The combination is administered orally to obtain a synergistic effect. The synergistic effect is obtained after 13 weeks or more such a after 14 weeks or more. after 15 weeks or more. after 16 weeks or more. after 17 weeks or more. after 18 weeks or more. after 19 weeks or more. after 20 weeks or more. after 21 weeks or more. after 22 weeks or more. after 23 weeks or more. after 24 weeks or more. after 25 weeks or more of after 26 weeks or more of treatment. The synergistic effect gives improved weight loss.
    Type: Application
    Filed: May 20, 2022
    Publication date: July 11, 2024
    Applicant: Empros Pharma AB
    Inventors: Jan Stefan Persson GRUDÉN, Anders FORSLUND, Ulf HOLMBÄCK, Jan Arvid SÖDERHALL, Göran ALDERBORN
  • Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
    Patent number: 11975105
    Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: May 7, 2024
    Assignee: EMPROS PHARMA AB
    Inventors: Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
  • MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS
    Publication number: 20200230063
    Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 23, 2020
    Applicant: EMPROS PHARMA AB
    Inventors: Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
  • Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
    Patent number: 10561617
    Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: February 18, 2020
    Assignee: EMPROS PHARMA AB
    Inventors: Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
  • MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS
    Publication number: 20170360715
    Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 21, 2017
    Applicant: EMPROS PHARMA AB
    Inventors: Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén